SenzaGen AB expands product portfolio to include respiratory sensitization

SenzaGen AB, a diagnostic spin-off company from Lund University, reports the launch of a new product for respiratory sensitization testing.

SenzaGen AB is a diagnostic company working to replace animal testing for sensitization predictions.

-“Sensitization through the lung is a growing issue and methods to predict if a chemical has a sensitization effect are limited”, says Anki Malmborg Hager, CEO in SenzaGen. Based on extensive research about the responses of the immune system in allergic reactions, SenzaGen has now launched a test that predicts the respiratory sensitization ability of chemicals based on the GARD methodology.

An international scientific article about the underlying research has been published in PLOS ONE, under the title “Prediction of Chemical Respiratory Sensitizers Using GARD, a Novel In vitro Assay Based on a Genomic Biomarker Signature”. http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0118808

SenzaGen´s first product, a skin sensitization test of chemicals, is already on the market.

About SenzaGen

SenzaGen AB is an early-phase diagnostics company based on strong research and know-how of the immune system and its reaction to hazardous agents, such as irritants and allergens. The company’s products are genetic tests for sensitizing agents, which have been designed based on how indicator cells react when exposed to a variety of chemicals.

SenzaGen AB was created to meet the international demand to replace existing animal testing for regulatory purposes and to provide novel tools for early decision-making in product development. SenzaGen AB services will offer the most accurate, animal-free in vitro testing option for manufacturers of cosmetics, chemicals, food, and pharmaceuticals.

SenzaGen AB is a spin-off company founded by researchers at Lund University to bring academic results to good use for society. The company is situated in facilities at Medicon Village, Lund, Sweden.

www.senzagen.com

For more information please contact:

Anki Malmborg Hager, CEO, SenzaGen AB

amh@senzagen.com

+46 768 284822

Tags:

About Us

About SenzaGen SenzaGen makes it possible to replace animal experiments with in vitro genetic testing to determine the allergenicity of the chemicals we come into contact with in our daily lives, such as for example in cosmetics, pharmaceuticals, food products and dyes. The company's patented tests are the most reliable on the market and provide more information than traditional evaluation methods. We ourselves sell the tests in Sweden and the USA, and we sell through partners in several other countries. Over the next few years the company will expand geographically, make alliances with more distribution partners and launch further unique tests. SenzaGen has its headquarters in Lund in Sweden and a subsidiary in San Francisco, USA. For more information visit www.senzagen.com About GARD GARD is a group of tests for assessing chemical skin sensitizers. The tests make use of genetic biomarkers for more than 200 genes which cover the entire immune reaction and are relevant to predicting the risk of hypersensitivity. The tests have up to 90% reliability. This compares with the current predominant test method, experiments on mice, which has an accuracy of 70-75%. SenzaGen's tests are also capable of measuring the potency of a substance's allergenic properties. Consequently GARD tests provide a much more comprehensive basis for determining whether a substance should be classified as an allergen than current testing methods.

Subscribe

Media

Media

Documents & Links